Stock 9966 ALPHAMAB ONCOLOGY
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Alphamab Oncology

Equities

9966

KYG0330A1013

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:05 2024-05-31 am EDT 		5-day change 1st Jan Change
2.54 HKD +4.53% Intraday chart for Alphamab Oncology -45.61% -61.75%
May. 29 Hong Kong Stocks Close Lower Following Mixed Session on Wall Street MT
May. 29 Alphamab's Phase 3 Trial for Pancreatic Cancer Treatment Fails to Reach Preset Statistical Endpoint; Shares Plunge 38% MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
TRACON Pharmaceuticals Reports Regulatory Approval of Envafolimab in China
AQ
Alphamab Oncology : VOLUNTARY ANNOUNCEMENT - ABSTRACTS AND E-POSTERS OF RESEARCH UPDATES ON KN046 AND KN026 FOR PRESENTATION AT 2021 ASCO ANNUAL MEETING
PU
Alphamab Oncology : (1) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES; (2) PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS; (3) PROPOSED RE-APPOINTMENT OF AUDITORS; AND (4) NOTICE OF ANNUAL GENERAL MEETING
PU
Alphamab Oncology : FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 11, 2021
PU
Alphamab Oncology : VOLUNTARY ANNOUNCEMENT - PRELIMINARY SAFETY TOLERABILITY AND EFFICACY RESULTS OF KN046 IN COMBINATION WITH NAB-PACLITAXEL IN PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER RELEASED FOR E-POSTER PRESENTATION AT 2021 AACR ANNUAL MEETING
PU
Alphamab Oncology : VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF CHIEF MEDICAL OFFICER AND CHIEF FINANCIAL OFFICER
PU
Alphamab Oncology : Reports Full Year 2020 Financial Results and Business Highlights
PR
Alphamab Oncology : ADOPTION OF THE RESTRICTED SHARE AWARD SCHEME
PU
Alphamab Oncology : Received U.S. FDA IND Clearance to Initiate A Phase II Pivotal Clinical Trial of KN046 (KN046-205,ENREACH-Thymic) in the U.S.
PR
Alphamab Oncology : VOLUNTARY ANNOUNCEMENT - IND APPROVAL RECEIVED FOR A PHASE II CLINICAL TRIAL OF KN046 IN THE U.S.
PU
TRACON Pharmaceuticals : Announces Acceptance of the Envafolimab NDA by the NMPA in China for Priority Review
AQ
TRACON Pharmaceuticals : Announces Acceptance of the Envafolimab NDA by the NMPA in China that was submitted by its Corporate Partners Alphamab Oncology and 3D Medicines
AQ
TRACON Pharmaceuticals : Announces Submission for Approval of Envafolimab with the NMPA in China by its Corporate Partners Alphamab Oncology and 3D Medicines
AQ
TRACON Pharmaceuticals : Highlights Updated Envafolimab Clinical Results in MSI-H/dMMR Colorectal Cancer
AQ
Alphamab Oncology : Collaborating in Innovative Medical R&D to combat the pandemic, Alphamab Oncology and Institut Pasteur Shanghai Announce Partnership to Co-develop COVID-19 Neutralizing Antibody
PR
Alphamab Oncology : and Sanofi Enter Collaboration on KN026 in HER2+ Breast Cancer
PR
Alphamab Oncology : Received U.S. FDA IND Approval to Initiate A Phase II Clinical Trial of KN046 For NSCLC in the United States
PR
Alphamab Oncology :, Simcere and 3D Medicines Announce Partnership to Develop and Commercialize Subcutaneous Injectable anti-PD-L1 Antibody for Oncology Indications in Mainland China
PR
Alphamab Oncology : Announces Clinical Supply Collaboration with Pfizer on KN026 in Combination with Ibrance(R) (palbociclib)
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 9966 Stock
  4. News Alphamab Oncology
  5. Press Releases